Smoldering multiple myeloma 40 years later: a story of unintended disease
- PMID: 33430658
- DOI: 10.1080/17474086.2021.1875815
Smoldering multiple myeloma 40 years later: a story of unintended disease
Abstract
Introduction: Smoldering multiple myeloma (SMM) is a clonal plasma cell (PC) disorder considered a prelude to MM due to its greater malignant potential compared to monoclonal gammopathy of undetermined significance (MGUS). Despite tectonic changes in the SMM landscape that occurred since it was first distinguished four decades ago, SMM continues to represent a complex and controversial entity causing a great deal of diagnostic and management turmoil.Areas covered: Author addresses increasingly complicated, ambiguous, as well as some overlooked and misjudged aspects of SMM such as the disease identity, relationship to its counterparts, MGUS and overt MM, its niche in the modern classification of monoclonal gammopathies and management. The PubMed search (1980-2020) was conducted and the current NCCN guidelines reviewed in reference to the diagnosis and treatment of smoldering multiple myeloma.Expert opinion: A plethora of clinical and biological evidence points to SMM as a source of the ongoing and expanding uncertainty of this condition and calls into question its authenticity as a discrete entity. Until comprehensive testing can predict the progression of pre-myeloma conditions with the utmost precision, attempts at preemptive treatments will fail to answer the basic question of who will benefit from the early treatment and who will not.
Keywords: Classification; MGUS; multiple myeloma; smoldering.
Similar articles
-
Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma.J Natl Compr Canc Netw. 2020 Dec 1;18(12):1720-1729. doi: 10.6004/jnccn.2020.7660. J Natl Compr Canc Netw. 2020. PMID: 33347744 Review.
-
Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.Eur J Intern Med. 2018 Dec;58:57-63. doi: 10.1016/j.ejim.2018.05.029. Epub 2018 Jun 12. Eur J Intern Med. 2018. PMID: 29907380 Review.
-
Smoldering multiple myeloma current treatment algorithms.Blood Cancer J. 2022 Sep 5;12(9):129. doi: 10.1038/s41408-022-00719-0. Blood Cancer J. 2022. PMID: 36064707 Free PMC article. Review.
-
SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma.Clin Lymphoma Myeloma Leuk. 2024 Oct;24(10):653-664. doi: 10.1016/j.clml.2024.03.008. Epub 2024 Mar 16. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38641486 Review.
-
Population-based screening cohort study reveals no association between monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), multiple myeloma (MM), and alopecia.Arch Dermatol Res. 2024 Sep 14;316(9):627. doi: 10.1007/s00403-024-03372-8. Arch Dermatol Res. 2024. PMID: 39276205 No abstract available.
Cited by
-
Immunotherapy of Multiple Myeloma: Promise and Challenges.Immunotargets Ther. 2021 Sep 9;10:343-371. doi: 10.2147/ITT.S306103. eCollection 2021. Immunotargets Ther. 2021. PMID: 34527606 Free PMC article. Review.
-
Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future.Int J Mol Sci. 2023 Oct 27;24(21):15674. doi: 10.3390/ijms242115674. Int J Mol Sci. 2023. PMID: 37958658 Free PMC article. Review.
-
Efficacy and Safety of Anti-CD38 Monoclonal Antibodies in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Randomized Clinical Trials.J Pers Med. 2024 Mar 29;14(4):360. doi: 10.3390/jpm14040360. J Pers Med. 2024. PMID: 38672988 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical